PRESS RELEASE




NUMBER OF SHARES AND VOTING RIGHTS OF
INNATE PHARMA AS OF JULY 3, 2025


Marseille, France, July 4, 2025, 7:00 AM CEST
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of
the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General
Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the
“Company”) releases its total number of shares outstanding as well as its voting rights as of
July 3, 2025:

Total number of shares outstanding: 92,183,523 ordinary shares
6,434 Preferred Shares 2016
7,581 Preferred Shares 2017
Total number of theoretical voting rights (1): 92,962,943
Total number of exercisable voting rights (2): 92,944,368

(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the
crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is
calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have
been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e.
130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. No voting rights attached to AGAP
2017.
(2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the
shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is
adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.



About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing
immunotherapies for cancer patients. Its innovative approach aims to harness the innate
immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its
ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody
Drug Conjugates (ADC) and monoclonal antibodies (mAbs).
Innate’s portfolio includes several ANKET® drug candidates to address multiple tumor types as
well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-
KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and
peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with
AstraZeneca in non-small cell lung cancer.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and
AstraZeneca, as well as leading research institutions, to accelerate innovation, research and
development for the benefit of patients.
Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on
Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.


Number of shares as of July 3, 2025 Page 1/3
PRESS RELEASE




Information about Innate Pharma shares

ISIN code FR0010331421
Ticker code Euronext: IPH Nasdaq: IPHA
LEI 9695002Y8420ZB8HJE29


Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the
meaning of applicable securities laws, including the Private Securities Litigation Reform Act of
1995. The use of certain words, including “anticipate,” “believe,” “can,” “could,” “estimate,”
“expect,” “may,” “might,” “potential,” “intend,” “should,” “will,” or the negative of these and
similar expressions, is intended to identify forward-looking statements. Although the Company
believes its expectations are based on reasonable assumptions, these forward-looking
statements are subject to numerous risks and uncertainties, which could cause actual results
to differ materially from those anticipated. These risks and uncertainties include, among other
things, the uncertainties inherent in research and development, including related to safety,
progression of and results from its ongoing and planned clinical trials and preclinical studies,
review and approvals by regulatory authorities of its product candidates, the Company’s
reliance on third parties to manufacture its product candidates, the Company’s
commercialization efforts and the Company’s continued ability to raise capital to fund its
development. For an additional discussion of risks and uncertainties, which could cause the
Company's actual results, financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs
de Risque") section of the Universal Registration Document filed with the French Financial
Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org
or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and
Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the
year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC,
or otherwise made public by the Company. References to the Company’s website and the AMF
website are included for information only and the content contained therein, or that can be
accessed through them, are not incorporated by reference into, and do not constitute a part of,
this press release.


In light of the significant uncertainties in these forward-looking statements, you should not
regard these statements as a representation or warranty by the Company or any other person
that the Company will achieve its objectives and plans in any specified time frame or at all.
The Company undertakes no obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise, except as required by law.


This press release and the information contained herein do not constitute an offer to sell or a
solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.




Number of shares as of July 3, 2025 Page 2/3
PRESS RELEASE




For additional information, please contact:
Investors Media Relations

Innate Pharma NewCap
Henry Wheeler Arthur Rouillé
Tel.: +33 (0)4 84 90 32 88 Tel.: +33 (0)1 44 71 00 15
Henry.wheeler@innate-pharma.fr innate@newcap.eu




Number of shares as of July 3, 2025 Page 3/3